Logo

JUNS

Jupiter Neurosciences, Inc.

JUNS

Jupiter Neurosciences, Inc. • NASDAQ
$1.23 ▲ 1.24% (+0.01)
Market Cap $42.22 M
52w High $19.51
52w Low $0.51
Dividend Yield 0%
P/E -5.33
Volume 12.07K
Outstanding Shares 34.47M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $2.297M ▲ $-2.288M ▼ 0% $-0.07 ▼ $-2.287M ▼
Q2-2025 $0 $2.265M ▲ $-2.253M ▼ 0% $-0.068 ▼ $-2.252M ▼
Q1-2025 $0 $1.538M ▲ $-1.529M ▼ 0% $-0.046 ▲ $-1.528M ▼
Q4-2024 $0 $1.458M ▲ $-1.528M ▼ 0% $-0.051 ▼ $-1.497M ▼
Q3-2024 $0 $493.547K $-591.021K 0% $-0.019 $-483.639K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $723.797K ▼ $2.576M ▼ $2.519M ▼ $57.417K ▼
Q2-2025 $1.878M ▼ $3.968M ▼ $2.628M ▲ $1.34M ▼
Q1-2025 $2.706M ▼ $4.963M ▼ $1.898M ▼ $3.065M ▼
Q4-2024 $3.77M ▲ $6.202M ▲ $2.03M ▼ $4.172M ▲
Q3-2024 $253 $85.546K $5.837M $-5.751M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-2.288M ▼ $-1.154M ▼ $0 $0 $-1.154M ▼ $-1.154M ▼
Q2-2025 $-2.253M ▼ $-828.222K ▲ $0 $0 $-828.222K ▲ $-828.222K ▲
Q1-2025 $-1.529M ▼ $-1.063M ▲ $0 $0 ▼ $-1.063M ▼ $-1.063M ▲
Q4-2024 $-1.528M ▼ $-3.696M ▼ $0 $7.465M ▲ $3.769M ▲ $-3.696M ▼
Q3-2024 $-591.021K $-42.598K $0 $28K $-14.598K $-42.598K

Five-Year Company Overview

Income Statement

Income Statement Jupiter Neurosciences looks like a classic early-stage biotech: essentially no product revenue yet and ongoing losses. Earnings per share have been negative for several years, which reflects spending on research, development, and overhead without commercial sales to offset those costs. The losses per share appear to be getting somewhat smaller over time, which may indicate tighter cost control or modest changes in share count, but overall the story is still one of building a pipeline rather than generating income. Future financial performance will hinge on clinical progress and eventual commercialization rather than current profit metrics.

Balance Sheet

Balance Sheet The balance sheet in this dataset is extremely light, showing very small asset levels, no reported debt, and equity hovering close to zero. That suggests a very small capital base and emphasizes how sensitive the company is to any change in funding or valuation. The lack of reported cash in the feed likely reflects data gaps rather than an actual zero balance, but it underlines that this is a lean, early-stage operation that likely depends on periodic capital raises, grants, or partnerships to support its programs. Financial flexibility and access to new funding will be critical points to watch.

Cash Flow

Cash Flow The cash flow data provided are essentially blank, which limits detailed analysis. In practice, companies at this stage almost always have negative operating cash flow as they pay for trials, research, and corporate costs, with no offsetting revenue. Cash inflows typically come from equity offerings, grants, or collaboration payments. For a business like this, the key questions are how fast it is burning cash, how many years of runway it has, and how dependent it is on future capital raises – none of which are visible in this dataset but are central risks to monitor.

Competitive Edge

Competitive Edge Jupiter’s competitive position rests on its JOTROL platform, which aims to make resveratrol meaningfully more effective and better absorbed, especially for brain-related conditions. Patents that extend well into the future, orphan drug status for at least one rare disease, and collaborations with major academic centers give it some protection and credibility. The dual strategy—targeting both serious neurological diseases and a broader consumer longevity market—could create multiple paths to recognition and potential revenue. However, it operates in a crowded space dominated by much larger pharmaceutical companies, and its advantage will ultimately depend on how strong its clinical results are and how well it executes partnering and commercialization.

Innovation and R&D

Innovation and R&D Innovation is the clear strength here. JOTROL is designed to overcome long-standing limitations of resveratrol by improving absorption and enabling brain penetration, which opens the door to several neurological and rare disease indications. The pipeline spans Parkinson’s, cognitive decline and early Alzheimer’s, Friedreich’s Ataxia, and other rare disorders, giving the company several shots on goal from a single technology base. On top of that, the planned Nugevia consumer products extend the same science into wellness markets, potentially creating earlier, smaller-scale commercialization. Still, all of this is research-driven and high risk: promising early studies do not guarantee success in larger trials, and substantial ongoing R&D investment will be required with uncertain outcomes.

Summary

Overall, Jupiter Neurosciences is a very early-stage, science-focused biotech with minimal current financial substance and a strategy that relies heavily on future success. The financial statements in this dataset show no revenue, continuing losses, and a very thin balance sheet, underscoring dependence on external funding. On the other side of the ledger, the company has a differentiated technology platform, intellectual property protection, academic partnerships, and a diversified pipeline that targets both rare diseases and large neurodegenerative conditions, plus a planned consumer brand. The story is therefore highly binary: future value will depend on clinical trial results, regulatory progress, the success of the consumer launch, and the company’s ability to secure sufficient financing and partnerships along the way, all of which carry considerable uncertainty.

NEWS

October 27, 2025 · 8:30 AM UTC

Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing

Read more